Scarica l'app Stockscreener
8.4298
6.71%
0.5298
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
What analysts say about Phathom Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Phathom Pharmaceuticals Inc. Stock Analysis and ForecastConsistent triple returns - jammulinksnews.com
What drives Phathom Pharmaceuticals Inc. stock priceTurbocharged investment results - PrintWeekIndia
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $17.50 - Defense World
Why Phathom Pharmaceuticals Inc. stock attracts strong analyst attentionShort Squeeze Radar - Newser
What makes Phathom Pharmaceuticals Inc. stock price move sharplyAnalyst Grade Signals - Newser
How Phathom Pharmaceuticals Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
How To Trade (PHAT) - news.stocktradersdaily.com
Phathom Pharmaceuticals: A Path to Profitability and a Billion-Dollar Horizon with Voquezna? - AInvest
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Yahoo Finance
Phathom Pharmaceuticals shares rise 1.47% premarket after Cidara Therapeutics closes $402.5 million stock offering. - AInvest
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism - Seeking Alpha
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewswire
Phathom Pharmaceuticals: Stock Awards Driving Shareholder Value to New Heights - AInvest
FDA Approval for VOQUENZA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC - Quantisnow
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom Pharmaceuticals Announces FDA Correction to Orange - GlobeNewswire
Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update - MarketScreener
Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA - Nasdaq
Phathom Pharmaceuticals Announces FDA Correction to Orange Book - GuruFocus
Phathom Pharmaceuticals (PHAT) Secures Extended Exclusivity for VOQUEZNA | PHAT Stock News - GuruFocus
FDA extends Phathom’s VOQUEZNA exclusivity period to 2032 By Investing.com - Investing.com Canada
FDA Grants 10-Year Exclusivity for Breakthrough GERD Drug VOQUEZNA: Major Win for Phathom - Stock Titan
PHAT Stock Surges: What Investors Need to Know - StocksToTrade
Transcript : Phathom Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade - MSN
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy (PHAT) - Seeking Alpha
Phathom Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Phathom Pharmaceuticals (PHAT) Price Target Increased Following FDA Ruling | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Receives Buy Rating from HC Wainw - GuruFocus
Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals (PHAT) Analyst Rating Update: Price Target Raised to $17.00 | PHAT Stock News - GuruFocus
H.C. Wainwright maintains Buy on Phathom stock, $20 target - Investing.com
Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald - MSN
Zak Mir takes a charting look at the USA Chartbreakers – Saturday 7th June 2025 - Share Talk
Phathom Pharmaceuticals (PHAT) Soars on FDA Approval and Market Exclusivity | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update - GuruFocus
FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT - GuruFocus
FDA Grants Phathom Pharmaceuticals (PHAT) Extended Exclusivity f - GuruFocus
4.91%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):